GSK plc Profile Avatar - Palmy Investing

GSK plc

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United …
Drug Manufacturers - General
GB, Brentford [HQ]
GSK/Financial Reporting

Income Statements

15 Sheets · Starting from 2023
In Million GBP. Margins, Growth Rates In %
Metric 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Revenue
28,368.00 28,392.00 27,387.00 26,431.00 26,505.00 23,006.00 23,923.00 27,889.00 30,186.00 30,821.00 33,754.00 34,099.00 34,114.00 29,324.00 30,328.00
EPS
1.36 0.40 1.31 1.15 1.41 0.72 2.18 0.24 0.39 0.92 1.17 1.44 1.37 1.22 1.22
Profit
20,988.00 20,800.00 20,055.00 18,537.00 17,920.00 15,683.00 15,070.00 18,599.00 19,844.00 20,580.00 21,891.00 22,395.00 22,511.00 19,770.00 21,252.00
Pre Tax
7,891.00 3,157.00 7,698.00 6,692.00 6,647.00 2,968.00 10,526.00 1,939.00 3,525.00 4,800.00 6,221.00 6,968.00 5,442.00 5,628.00 6,069.00
ETR
28.16 41.31 29.10 29.11 15.33 4.62 20.46 45.23 38.47 15.71 15.32 8.32 6.36 12.56 12.46
Net
5,531.00 1,634.00 5,261.00 4,565.00 5,436.00 2,756.00 8,422.00 912.00 1,532.00 3,623.00 4,645.00 5,749.00 4,385.00 4,921.00 4,928.00
EBITDA
9,766.00 5,970.00 9,589.00 8,585.00 8,547.00 5,721.00 12,302.00 4,536.00 7,146.00 7,358.00 10,129.00 8,484.00 8,786.00 8,805.00 9,287.00
Operating Income
8,425.00 3,783.00 7,807.00 7,392.00 7,028.00 3,597.00 10,322.00 2,598.00 4,087.00 5,483.00 6,961.00 7,783.00 6,201.00 6,433.00 6,993.00
Interest Income
70.00 116.00 90.00 79.00 61.00 68.00 104.00 72.00 65.00 81.00 98.00 44.00 28.00 76.00 55.00
Loss
-19,943.00 -24,609.00 -19,580.00 -20,295.00 -20,601.00 -19,409.00 -21,316.00 -25,291.00 -26,099.00 -25,338.00 -26,793.00 -26,316.00 -27,913.00 -22,891.00 -23,335.00
Cost of Revenue
-7,380.00 -7,592.00 -7,332.00 -7,894.00 -8,585.00 -7,323.00 -8,853.00 -9,290.00 -10,342.00 -10,241.00 -11,863.00 -11,704.00 -11,603.00 -9,554.00 -9,076.00
Operating Expenses
-12,563.00 -17,017.00 -12,248.00 -12,401.00 -12,016.00 -12,086.00 -12,463.00 -16,001.00 -15,757.00 -15,097.00 -14,930.00 -14,612.00 -16,310.00 -13,337.00 -14,259.00
Depreciation and Amortization
-1,271.00 -2,071.00 -1,677.00 -1,085.00 -1,415.00 -2,026.00 -1,862.00 -1,861.00 -2,981.00 -1,763.00 -2,996.00 -624.00 -2,524.00 -2,298.00 -2,294.00
Interest Expenses
-783.00 -831.00 -799.00 -808.00 -767.00 -727.00 -757.00 -736.00 -734.00 -798.00 -912.00 -892.00 -784.00 -879.00 -775.00
Other Expenses
-534.00 -626.00 -109.00 -700.00 -381.00 -629.00 -7,799.00 -4,147.00 -2,618.00 -683.00 -740.00 -815.00 -759.00 -805.00 -924.00
WA Shares Outstanding
4,055.00 4,068.00 4,022.00 3,929.00 3,864.00 3,846.00 3,864.00 3,888.00 3,908.00 3,931.00 3,957.00 3,980.00 3,202.00 4,026.00 4,052.00
End of GSK's Analysis
CIK: 1131399 CUSIP: 37733W204 ISIN: US37733W2044 LEI: - UEI: -
Secondary Listings